​Important: Please read instructions thoroughly before starting the late-breakthrough abstract submission.

 

The late-breakthrough abstract submission process is intended for cutting edge, high-level science (both basic and clinical) and is not intended as an extension of the general abstract submission process.

 

NEW: $50 USD charge per abstract submission

 

The content of the abstract must be related to one of the following topics. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

​

Main Topics

• Acquired and Critical Care Bleeding

• Antithrombotic and Fibrinolytic Therapies

• Arterial Disease

• Coagulation Factors and Cofactors

• Coagulation Modifiers, Anticoagulants, and von Willebrand Factor

• Diagnostics, OMICs, and Advanced Technologies

• Fibrinogen, Factor XIII, and Fibrinolysis

• Hemophilia and other Inherited Bleeding Disorders and Inhibitors

• Nurses and Allied Health

• Pediatric Hemostasis and Thrombosis

• Platelet Disorders

• Platelets and Megakaryocytes

• Vascular Biology, Blood Cells, and Immunothrombosis

• Venous Disease

• Women's Hemostasis and Thrombosis

​

Sub-Topics

Acquired and Critical Care Bleeding

• Antithrombotic Drug-Associated Bleeding

• Coagulopathy of Liver and Renal Disease

• Coagulopathy of Other Systemic Diseases

• Coagulopathy of Trauma

• Massive Transfusion Management

• Perioperative Bleeding

Antithrombotic and Fibrinolytic Therapies

• Current Anticoagulants

• Future Anticoagulants

• Current Antiplatelet Agents

• Future Antiplatelet Agents

• Current and Future Fibrinolytic Therapies

• Antithrombotic Stewardship

Arterial Disease

• Atrial Fibrillation

• Cerebrovascular Disease

• Coronary Artery and Other Cardiac Diseases

• Peripheral Artery Disease

Coagulation Factors and Cofactors

• Common Pathway

• Contact Pathway

• Non-hemostatic Roles of Coagulation Proteins

• Protein Structure and Function

• Synthesis and Biochemistry

• TF and TFPI Pathway

Coagulation Modifiers, Anticoagulants, and von Willebrand Factor

• ADAMTS13 and Other Proteases

• Antithrombin and Other Serpins

• Non-hemostatic Roles of Anticoagulant Proteins

• Protein C/S Pathway

• von Willebrand Factor

Diagnostics, OMICs, and Advanced Technologies

• Artificial Intelligence/Machine Learning

• Genomics and Transcriptomics

• Mathematical and Computational Models

• Novel Experimental Models of Hemostatic and Thrombotic Diseases

• Novel Clinical Laboratory Diagnostic Methods

• Proteomics, Metabolomics, and Lipidomics

Fibrinogen, Factor XIII, and Fibrinolysis

• Factor XIII and Other Transglutaminases

• Fibrinogen Structure and Function

• Fibrinolysis and Proteolysis

Hemophilia and other Inherited Bleeding Disorders and Inhibitors

• Acquired Factor Deficiencies

• Gene Therapy

• Congenital Hemophilia with Inhibitors

• Joint Health

• Novel Hemostatic Therapies

• Rare Factor Deficiencies

• Vascular Disorders

• Von Willebrand Disease

Nurses and Allied Health

• Nurses and Allied Health

Pediatric Hemostasis and Thrombosis

• Bleeding and Thrombotic Issues in Adolescence

• Neonatal Coagulation Disorders

• Pediatric Bleeding and Thrombosis

• Perioperative and Critical Care

Platelet Disorders

• Acquired Platelet Disorders

• Immune Thrombocytopenia - ITP, HIT, PF4 Antibodies

• Inherited Platelet Disorders

• Myeloproliferative Neoplasms and Clonal Disorders

• Thrombotic Microangiopathy

Platelets and Megakaryocytes

• Megakaryocyte Biology

• Non-hemostatic Roles of Platelets

• Platelet Biology

• Receptors and Signaling

Vascular Biology, Blood Cells, and Immunothrombosis

• Blood Vessel Structure and Function

• Coagulation and Cancer

• Coagulation and Non-Malignant Comorbidities

• Endothelial Cell Biology

• Extracellular Vesicles

• Infection and Immunity in Immunothrombosis and Bleeding

• Inflammation and Thrombosis

• Red Cell Disorders and Coagulation

Venous Disease

• Cancer-associated Thrombosis

• Deep and Superficial Venous Thrombosis

• Long-term Consequences of VTE - CTEPH, PTS, etc.

• Pulmonary Embolism

• Thrombophilia

• Unusual Site VTE

Women's Hemostasis and Thrombosis

• Hormonal Modulation of Coagulation

• Menstrual Bleeding Disorders

• Pregnancy

• Hormonal Modulation of Coagulation

• Menstrual Bleeding Disorders

• Pregnancy

 

Statement on the Use of AI

The ISTH recognizes the use of generative artificial intelligence (AI) as a powerful tool for educators and researchers and encourages its responsible and ethical use. If any form of generative AI is utilized for this abstract, it must be clearly acknowledged. It is expected that authors will review any AI-generated copy, figures, images, citations, or statements for accuracy and edit accordingly.

 

How to Submit an Abstract

• Delegates, who would like to present their work at the congress, are invited to submit a late-breakthrough abstract. If accepted the late-breakthrough abstract will be presented as and oral communication.

• ISTH Members and Non-Members are invited to submit abstracts.

• There is a $50 USD fee per abstract to submit.

• Abstracts can only be submitted online via the abstract submission website that can be found in the section “Abstract Guidelines” on the official ISTH Congress website. Abstracts sent by post or email will not be accepted. No exceptions will be made.

• The submitter may be required to create a new user account in order to submit an abstract. Once logged in you will be able to submit your abstract.

• Abstracts can be saved in "Work In Progress” status and be re-edited and modified until the submission deadline (May 14, 2025, 17:00 Eastern Standard Time (U.S.).

• You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.

• The submitted/Work in Progress abstracts cannot be edited after the submission deadline.

• Only abstracts that have been submitted properly will be considered for the congress.

• Any technical questions regarding the submission website should be sent to abstracts@isth.org.

 

Late-Breakthrough Guidelines

• Late-breakthrough abstracts will not be submitted during the regular abstract submission process. Late-breakthrough abstracts will be submitted following the below timeline:

  • Submission Site Opens: May 7, 2025

  • Submission Site Closes: May 14, 2025

• Late-breakthrough abstracts should highlight novel studies of high impact. Abstracts submitted will be considered if the study is ground-breaking and includes novel data. The abstract should not have been previously published or presented in any format. Both basic and clinically focused abstracts can be submitted.

• The late-breakthrough abstract deadline is not intended to be an extension of the regular submission deadline.

• The review and selection process will be highly competitive. No more than ten abstracts will be selected to be featured in two Oral Communication Sessions. If your abstract is not chosen to be included in the Late-Breakthrough Oral Communication Session, it will be rejected. There are no late-breakthrough posters.
   

General Guidelines

• The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.

• Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English-speaking authors are encouraged to have their abstract checked for grammar and spelling.

• Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.

• Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected. Similarly, do not submit a copy or close copy of an abstract under more than one (1) topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.

• All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

• No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline

​

ISTH Embargo Policy

You can view the ISTH Embargo Policy here.

​

Prior Publication

Authors will be permitted to submit their abstract to the ISTH 2025 Congress and another journal/meeting as long as the data in the abstract has not been published/presented to a scientific audience at the time of submission. Press releases may be allowed only if general information and no primary detailed data is included.

 

Abstracts submitted to regional or national meetings (no larger than 2,000 attendees) can be submitted to the ISTH 2025 Congress for consideration for inclusion in the program.

​

If you have questions regarding prior publication please contact us at abstracts@isth.org.

 

Preparing an Abstract for Submission
Authors and Co-Authors

• The presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

• The presenting author of the abstract must be registered for the congress. Abstract will be withdrawn if registration is not completed by June 9, 2025.

• The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived and no virtual presentations will be permitted.

• A maximum of 20 authors is permitted on each abstract, plus one (1) group.

• Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-authors.

• New: Based on current ACCME accreditation guidelines, an employee of industry may be eligible to speak in an accredited session if there is not a perceived conflict of interest. We encourage industry to submit their abstracts and complete the COI questions within the submission system in order to be considered. If the planning committee deems there to be any conflict of interest, you may be asked to change the presenting author of your abstract presentation.

 

Conflict of Interest

• It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. If your abstract is chosen for a late-breakthrough session, the presenting author and all co-authors will need to complete a conflict of interest disclosure upon acceptance.

Abstract Body

• While the submission system does not limit your word count, please keep the length of your abstract to a maximum of 300 words. This does not include the author’s details, titles, tables and figures.

• Title: Clearly indicate the nature of the investigation. The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts. Please note that the title has a character count of 100 characters.

• Background

• Aims

• Methods: Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study

• Results: Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the abstract text.

• Conclusion (or Conclusions): Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

• Reason Why Your Abstract Should be Considered “Late-Breakthrough”

• Other Items for Consideration

  • In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.

  • If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.

  • Please indicate the funding agency of your work if applicable. There is not a specific area to enter this information, it will need to be included as part of the abstract text.

  • Abbreviations should be defined.

  • If off-label use of drugs was involved in the study, please state this clearly.

Figures and Table

• Figures and tables may be submitted with a maximum file size is 2 MB w. Figures are allowed in the following formats: PNG, GIF, JPG.

• Your abstract may contain two (2) figures or tables; this can be a combination of the following: two (2) figures, two (2) tables, or one (1) figure and one (1) table.

• You will be asked to include a heading for each of your figures/tables to be included as part of the formal published abstract supplement.

 

After Submission

An international panel of experts will review the abstracts. Each abstract will be reviewed by 3-5 different experts. The presenting author will be notified in early June, at the email address provided during submission, about whether or not their abstract has been accepted.

The reviewers will judge the abstracts according to the following criteria:

• Is the abstract original?

• Does it address an important scientific question?

• Is the abstract clearly written with all salient facts?

• Does the work adhere to ethical guidelines?

• Is there evidence of statistical method if appropriate?

• Are the conclusions justified by the results?

​Please note:

• No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.

• The review and selection process for Late-Breakthrough Abstracts will be highly competitive. No more than ten abstracts will be selected and featured in two Oral Communication Sessions. If your abstract is not chosen to be included in the Late-Breakthrough Oral Communication Session, it will be rejected.

• Late-breakthrough abstracts will be published on the day of the Late-breakthrough Oral Communication session. Late-breakthrough titles will be made available prior to the congress.

• All accepted Late-breakthrough abstracts will be published as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH) and will be made available on the ISTH Congress website in the months following the congress.

​​

Withdrawal Policy
If authors wish to withdraw their abstracts from presentation or publication they are requested to notify ISTH via e-mail to abstracts@isth.org before June 9, 2025. Withdrawn abstracts will not be presented nor will these be published.

 

Technical Requirements
The online abstract submission system works best with Google Chrome and Mozilla Firefox. Cookies and JavaScript need to be enabled.

 

Language Setting of Your Keyboard
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed.

To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial.  

In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.